<code id='9797C7B276'></code><style id='9797C7B276'></style>
    • <acronym id='9797C7B276'></acronym>
      <center id='9797C7B276'><center id='9797C7B276'><tfoot id='9797C7B276'></tfoot></center><abbr id='9797C7B276'><dir id='9797C7B276'><tfoot id='9797C7B276'></tfoot><noframes id='9797C7B276'>

    • <optgroup id='9797C7B276'><strike id='9797C7B276'><sup id='9797C7B276'></sup></strike><code id='9797C7B276'></code></optgroup>
        1. <b id='9797C7B276'><label id='9797C7B276'><select id='9797C7B276'><dt id='9797C7B276'><span id='9797C7B276'></span></dt></select></label></b><u id='9797C7B276'></u>
          <i id='9797C7B276'><strike id='9797C7B276'><tt id='9797C7B276'><pre id='9797C7B276'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:57943
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more
          The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies
          The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

          BiogenCEOChristopherViehbacherSTATTwoyearsafterabigscientificswingnearlypushedBiogentothebrink,CEOCh

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Senators: Long

          Sen.EdMarkeyofMassachusetts(above)andSen.JoeManchinofWestVirginiahadwordsofwarningforFDACommissioner